(ETON)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| Name | Position |
|---|---|
| Danka Radosavljevic | Executive Vice President of Operations |
| Mr. David C. Krempa | Chief Business Officer |
| Mr. James R. Gruber CPA | CFO, Treasurer & Secretary |
| Mr. Scott Grossenbach | Senior Vice President of Sales Operations |
| Mr. Sean E. Brynjelsen | President, CEO & Director |
| Ms. Ipek Erdogan-Trinkaus | Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-19 | 10-K | eton20251231_10k.htm |
| 2026-03-06 | S-8 | eton20260223_s8.htm |
| 2026-03-02 | 8-K | eton20260223c_8k.htm |
| 2026-02-02 | 8-K | eton20260130_8k.htm |
| 2025-12-04 | 8-K | eton20251203_8k.htm |
| 2025-11-19 | S-8 | eton20251001_s8.htm |
| 2025-11-18 | 8-K/A | eton20250314_8ka.htm |
| 2025-11-06 | 10-Q | eton20250930_10q.htm |
| 2025-08-07 | 10-Q | eton20250630c_10q.htm |
| 2025-07-08 | 8-K | eton20250702_8k.htm |